US 10314850
Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted A61KA61K31/567A61K31/585
Quick answer
US patent 10314850 (Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients) held by Corcept Therapeutics Incorporated expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K31/567, A61K31/585, A61P, A61P3/10